Ara 290 vs CJC-1295 with DAC
Extensively Studied vs Well Studied
synergistic Mechanism-based · 47% Ara 290 and CJC-1295 with DAC work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
Ara 290 CJC-1295 with DAC
Weight 1,257 Da 3,647.28 Da
Half-life ~20 minutes (SubQ), ~2 minutes (IV) 6-8 days
Chain 11 amino acids 30 amino acids
Type Engineered peptide GHRH analog with DAC
Key Benefits
Ara 290
01 Proven tissue protection
02 Nerve regeneration
03 Anti-inflammatory effects
04 Excellent safety profile in clinical trials
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
Dosing Protocols
Ara 290
4 mg daily / Once daily
Neuropathy Treatment 4 mg daily Once daily
Tissue Protection 1-8 mg daily Once daily
Acute Intervention 2 mg 3x weekly
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
Side Effects
Ara 290
Excellent safety profile in clinical trials with no serious drug-related adverse events
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
Contraindications
Recent anti-TNF therapy (within 6 months)
EPO use (within 2 months)
Pregnancy
BMI > 34 kg/m²
Diabetes history
Cancer history
Predisposed sleep apnea
Research Evidence
Ara 290 CJC-1295 with DAC
Status Extensively Studied Well Studied
References 5 studies 4 studies
Latest 2024 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.